Additionally, new medications and therapeutic approaches like sodium-glucose cotransporter 2 (SGLT2) inhibitors [42, 43] improve both renal and heart function in CHF patients, thus further enhancing their long-term prognosis. The gene discussed is SLC5A2; the disease is congestive heart failure.